ReviewFEBS open bio2026
Exploring the influence of lactoferrin on wound healing and related signaling pathways: a systematic review.
Review in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review evaluates the therapeutic efficacy and biological mechanisms of Lactoferrin (Lf) in the wound healing process. The objective was to synthesize evidence regarding its multifunctional role in cellular regeneration, gene modulation, and antimicrobial protection. From an initial screening of 1846 records, 11 in vitro studies (2001-2023) met the eligibility criteria. The synthesized data demonstrate that Lf significantly accelerates the migration and proliferation of human keratinocytes and fibroblasts. At the molecular level, Lf upregulates critical regenerative genes, specifically HAS2 (hyaluronan synthesis) and COL1A1 (collagen type I). Furthermore, Lf exhibits potent inhibitory effects against biofilm formation and bacterial growth, with high efficacy reported against Staphylococcus aureus and Escherichia coli. Thus, Lf acts as a pivotal bioactive agent that bridges regenerative stimulus with antimicrobial defense across all healing phases. Its ability to modulate the extracellular matrix and suppress pathogens suggests it to be a candidate for advanced wound care and regenerative therapies. These findings establish a robust biological rationale for transitioning toward clinical-stage bioprospecting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.